10 results on '"AGABITI‐ROSEI, E."'
Search Results
2. Macro and microvasculature in hypertension: therapeutic aspects
- Author
-
Safar, M E, Rizzoni, D, Blacher, J, Muiesan, M L, and Agabiti-Rosei, E
- Published
- 2008
- Full Text
- View/download PDF
3. Circulating adhesion molecules and carotid artery structural changes in patients with noninsulin-dependent diabetes mellitus
- Author
-
Rizzoni, D, Muiesan, M L, Porteri, E, Castellano, M, Salvetti, M, Monteduro, C, De Ciuceis, C, Boari, G, Valentini, U, Cimino, A, Sleiman, I, and Agabiti-Rosei, E
- Published
- 2003
- Full Text
- View/download PDF
4. Night time blood pressure and cardiovascular structure in a middle-aged general population in northern Italy: the Vobarno Study
- Author
-
Salvetti, M, Muiesan, ML, Rizzoni, D, Bettoni, G, Monteduro, C, Corbellini, C, Viola, S, and Agabiti-Rosei, E
- Published
- 2001
- Full Text
- View/download PDF
5. Echocardiography in clinical practice: the burden of arterial hypertension. A multicenter Italian survey
- Author
-
Francesca Negri, Alberto Morganti, Enrico Agabiti-Rosei, G. De Simone, Giuliano Tocci, Cesare Cuspidi, Valentina Giudici, N. De Luca, M.L. Muiesan, Anna Capra, Cuspidi, C, Negri, F, Giudici, V, Capra, A, Muiesan, M, Agabiti rosei, E, De Simone, G, De Luca, N, Tocci, G, Morganti, A, Muiesan, Ml, Agabiti Rosei, E, DE SIMONE, Giovanni, DE LUCA, Nicola, and Morganti, A.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Heart Valve Diseases ,Myocardial Ischemia ,Left ventricular hypertrophy ,Body Mass Index ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,medicine ,Prevalence ,Humans ,LV hypertrophy ,echocardiography, burden of arterial hypertension ,Aged ,Body surface area ,Heart Failure ,business.industry ,Echo (computing) ,Smoking ,Arrhythmias, Cardiac ,Middle Aged ,medicine.disease ,Clinical Practice ,Diabetes Mellitus, Type 2 ,Italy ,Echocardiography ,Hypertension ,Cardiology ,Female ,Hypertrophy, Left Ventricular ,business ,Wall thickness ,Body mass index - Abstract
Little information is available about the burden of hypertension on echo-lab activity in current practice. The aim of the present nation-wide survey in outpatient echo-labs was to investigate the prevalence rates of (1) echo examinations performed for the evaluation of hypertensive cardiac damage; (2) reports providing quantitative data on left ventricular (LV) structure and geometry; (3) LV hypertrophy (LVH) in hypertensives referred to echo labs. The study was carried out in 14 outpatient echo-labs across Italy. Prescriptions written by general practitioners were used to identify the indications for the examinations. Estimates of LVH were derived from original echo reports or were calculated from LV primary measures, when available, with Devereux's formula in a post-analysis. Echo examination was performed in 2449 subjects (1245 men and 1204 women); hypertension was the indication for echo in 745 (30.4%) cases. In this subgroup, LV mass (LVM), LVM indexed to body surface area, LVM indexed to height 2.7 and relative wall thickness ratio were reported in 58, 59, 54 and 52%, respectively. LVH was present in 53% of untreated hypertensives and, among treated patients, in 45 and 65% of those with and without blood pressure control, respectively. Our findings show that (1) hypertension accounts for approximately one-third of echo examinations performed in clinical practice; (2) a large fraction of echo reports do not provide quantitative data on LVM and LV geometry, (3) LVH is highly prevalent in hypertensives referred to echo labs for assessment of cardiac damage. © 2010 Macmillan Publishers Limited All rights reserved.
- Published
- 2009
6. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (the SILVER trial). Study of Irbesartan in Left VEntricular hypertrophy Regression.
- Author
-
Cohen A, Bregman B, Agabiti Rosei E, Williams B, Dubourg O, Clairefond P, Brudi P, Gosse P, and Guéret P
- Subjects
- Adolescent, Adult, Blood Pressure drug effects, Double-Blind Method, Echocardiography, Female, Follow-Up Studies, Humans, Hypertension complications, Hypertension diagnostic imaging, Hypertrophy, Left Ventricular diagnostic imaging, Hypertrophy, Left Ventricular etiology, Irbesartan, Male, Treatment Outcome, Antihypertensive Agents therapeutic use, Biphenyl Compounds therapeutic use, Calcium Channel Blockers therapeutic use, Felodipine therapeutic use, Hypertension drug therapy, Hypertrophy, Left Ventricular drug therapy, Tetrazoles therapeutic use
- Abstract
The SILVER (Study of Irbesartan in Left VEntricular hypertrophy Regression) trial is designed to test the hypothesis that the newly developed angiontensin-II receptor antagonist, irbesartan, will produce a greater reduction in left ventricular (LV) mass than felodipine ER, in a population of hypertensive patients defined by seated diastolic blood pressure (SeDBP) in the range 95-115 mmHg or seated systolic blood pressure (SeSBP) in the range 160-200 mm Hg. A population of 360 men and women of non-childbearing potential, >18 years of age, with hypertension, newly diagnosed or after a 3-week washout from previous anti-hypertensive or vasodilator therapies, will be randomised at approximately 80-90 European sites. Add-on therapy with hydrochlorothiazide and atenolol will be allowed for blood pressure control. Patients will be studied by two-dimensional and M-mode echocardiography at baseline (central validation of LV hypertrophy), on randomisation day, and after 6 and 12 months randomised therapy. Blinded analysis of echocardiograms will be performed at a central laboratory, which will provide measurements of the LV mass index (LVMI), determined by M-mode readings according to Devereux formula and using the Penn convention. The primary end-point of the study will be the change in LVMI from baseline to 12 months. The study power is 90% to detect differences between groups from baseline of approximately 8 g/m2.
- Published
- 1998
- Full Text
- View/download PDF
7. Left ventricular structural characteristics in Cushing's syndrome.
- Author
-
Fallo F, Budano S, Sonino N, Muiesan ML, Agabiti-Rosei E, and Boscaro M
- Subjects
- Adolescent, Adult, Blood Pressure, Cushing Syndrome surgery, Echocardiography, Female, Heart Ventricles diagnostic imaging, Humans, Hydrocortisone urine, Hypertension pathology, Hypertrophy, Left Ventricular pathology, Male, Middle Aged, Cushing Syndrome pathology, Heart Ventricles pathology
- Abstract
The aim of the present study was to assess structural characteristics of the left ventricle by echocardiography in a group of patients with Cushing's syndrome compared with a control population. Eighteen patients with Cushing's syndrome and 18 controls, matched for sex, age, body weight, body surface area, blood pressure (BP) and duration of hypertension were investigated by M-mode (2-D derived) echocardiography. In each of the two groups, 11 of 18 subjects were hypertensive. Relative wall thickness (RWT) was above normal (> 0.45) in 11 (five normotensive and six hypertensive) of 18 patients with Cushing's syndrome and in two (hypertensive) of 18 controls. Left ventricular mass index was abnormal in three (one normotensive and two hypertensive) patients with Cushing's syndrome and in four hypertensive controls. All other systolic function indices were within normal and similar in both groups. No correlation was found between RWT and BP as well as between RWT and urinary cortisol levels in patients with Cushing's syndrome. A significant correlation was found between RWT and duration of disease. Echocardiography after successful surgery showed normalisation of RWT in five of six patients in whom it was previously abnormal. Our data suggest that time factor, i.e. long-lasting exposure to increased cortisol, rather than hormone or BP levels is the most relevant determinant of left ventricular concentric remodeling in patients with Cushing's syndrome.
- Published
- 1994
8. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
- Author
-
Agabiti-Rosei E, Muiesan ML, Rizzoni D, Zulli R, Calebich S, Beschi M, Castellano M, and Muiesan G
- Subjects
- Adrenergic alpha-Antagonists adverse effects, Adrenergic alpha-Antagonists therapeutic use, Adult, Aldosterone blood, Antihypertensive Agents adverse effects, Blood Pressure drug effects, Blood Pressure physiology, Cardiomegaly etiology, Catecholamines blood, Diastole physiology, Dose-Response Relationship, Drug, Doxazosin, Drug Therapy, Combination, Female, Heart Rate drug effects, Heart Rate physiology, Heart Ventricles pathology, Humans, Hydrochlorothiazide therapeutic use, Hypertension complications, Lipids blood, Male, Middle Aged, Organ Size, Prazosin adverse effects, Prazosin therapeutic use, Renin blood, Rest physiology, Stress, Physiological physiopathology, Systole physiology, Time Factors, Antihypertensive Agents therapeutic use, Cardiomegaly drug therapy, Hypertension drug therapy, Prazosin analogs & derivatives
- Abstract
The aim of this study was to evaluate the effect of antihypertensive treatment with doxazosin on left ventricular anatomy and function. Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3). Blood pressure was significantly reduced (Anova P less than 0.05), while heart rate did not change. A significant reduction of left ventricular mass index (from 128.5 +/- 26 to 114 +/- 23 g/m2, at the end of phase 1 and 3 respectively, P less than .001)) was observed. Before and during treatment left ventricular systolic function, both at rest and during stress (handgrip and cold pressor tests), evaluated by fractional shortening as related to end-systolic stress, in every case within 95% confidence limits, was calculated in normal subjects. Diastolic function, as evaluated by the ratio between peak early and atrial velocities of transmitral flow examined by pulsed doppler was significantly improved. Plasma catecholamine concentrations, plasma renin activity and plasma aldosterone did not change. A significant reduction of plasma cholesterol concentration was observed. These results confirm that doxazosin is a well tolerated and effective antihypertensive drug, with a favourable effect on blood lipids and they indicate that its longterm administration can induce a significant reduction of left ventricular mass.
- Published
- 1992
9. Reversal of cardiovascular structural changes during long-term antihypertensive therapy.
- Author
-
Agabiti-Rosei E and Muiesan ML
- Subjects
- Arrhythmias, Cardiac physiopathology, Arteries pathology, Cardiomegaly pathology, Cardiovascular System drug effects, Heart physiopathology, Humans, Hypertrophy, Lung physiopathology, Reflex drug effects, Sympathomimetics pharmacology, Time Factors, Vascular Resistance drug effects, Antihypertensive Agents therapeutic use, Cardiovascular System pathology
- Abstract
Several prospective epidemiological and clinical studies have indicated that regression of cardiovascular alterations, preferably at an early stage, is a desirable goal in the treatment of hypertension. The results of a large number of studies have indicated that many antihypertensive drugs can produce a significant regression of cardiovascular structural changes in hypertensive patients. However, it has not been established whether a complete 'normalisation' may occur. Further studies are needed to identify factors that modulate regression of cardiac and vascular smooth muscle hypertrophy. Most important, it remains to be clarified whether regression of cardiovascular structural changes significantly improves prognosis per se independently from blood pressure reduction.
- Published
- 1991
10. Albuminuria induced by exercise in hypertensive type I and type II diabetic patients: a randomised, double-blind study on the effects of acute administration of captopril and nifedipine.
- Author
-
Romanelli G, Giustina A, Cravarezza P, Caldonazzo A, Agabiti-Rosei E, and Giustina G
- Subjects
- Adolescent, Adult, Albuminuria etiology, Albuminuria physiopathology, Blood Pressure drug effects, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 physiopathology, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 physiopathology, Diabetic Nephropathies complications, Diabetic Nephropathies physiopathology, Diabetic Nephropathies urine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hypertension complications, Hypertension physiopathology, Male, Middle Aged, Time Factors, Albuminuria drug therapy, Captopril therapeutic use, Diabetes Mellitus, Type 1 urine, Diabetes Mellitus, Type 2 urine, Exercise physiology, Hypertension urine, Nifedipine therapeutic use
- Abstract
Physical exercise can increase urinary albumin excretion rate (UAER) in diabetic patients without microalbuminuria at rest (stage II diabetic nephropathy) or with baseline microalbuminuria (stage III diabetic nephropathy). The aim of this study was to compare the acute effects of captopril, an ACE inhibitor, and nifedipine, a calcium channel blocker, on exercise-induced microalbuminuria in hypertensive insulin-dependent (Type I) and non-insulin-dependent (Type II) diabetic patients with early stage nephropathy. Non-obese diabetic patients, 13 Type I (7 with stage II and 6 with stage III nephropathy) and 14 Type II (6 with stage II and 8 with stage III nephropathy), with hypertension, WHO stages I-II, underwent five submaximal cycloergometric tests: the first two in basal conditions, the other three after 24 hour administration of captopril (25 mg twice daily), placebo (1 tab twice daily) or nifedipine AR (20 mg twice daily) according to a randomised, double-blind design. Acute administration of both captopril and nifedipine was able to reduce exercise-induced microalbuminuria in hypertensive Type I and Type II diabetic patients regardless of the stage of their nephropathy. Captopril reduced systolic blood pressure less than nifedipine, in both Type I and Type II diabetics, but was more effective than nifedipine in blunting exercise-induced microalbuminuria, especially in Type I diabetics.
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.